Cadila Healthcare has received final approval for Zolmitriptan tablets USP, from the USFDA.

The company has received final approval to market Zolmitriptan Tablets, 2.5 mg and 5 mg, used to treat migraines. It relieves headache, pain, and other migraine symptoms (including nausea, vomiting and sensitivity to light/sound). Further, these tablets will be manufactured at the group’s manufacturing facility at Moraiya, Ahmedabad.

Read EquityPandit’s Technical Analysis of Nifty Pharma